why choose us

First received: July 11, 2023

Clinical Trial: Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia

Study Status: Completed

Recruit Status: RECRUITING

Condition: Waldenstrom Macroglobulinemia

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

Brief Summary: This study will evaluate the safety and efficacy of the BCL2 inhibitor BGB-11417 in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) in 3 cohorts.

Read more